

Oncology trials

Oncology enrollment enhancement: The Just-In-Time approach

Oncology clinical trials represent a special challenge for biopharmaceutical companies. When oncology research sites enroll, it takes an average of more than eight months from protocol outreach to site activation.

Oncology trials often take several months to open for patient enrollment. Industry-sponsored studies take a median of 170 days (~5.6 months) to activate, and only 9% open within 90 days.¹ Longer startup times can also put enrollment at risk—studies with stronger enrollment performance opened about 46 days sooner than those that struggled to reach their accrual goals.²


Faster study openings improve enrollment success



113+ pre-qualified sites



294+ investigators



Zero non-enrolling sites in the Just-In-Time community

Oncology enrollment enhancement uses a Just-In-Time methodology to jump-start study enrollment. We provide confirmed availability of pre-identified patients from pre-qualified sites in our community of over 113+ sites with over 294+ research-experienced investigators. This turn-key service augments your traditional trial approach and provides the first study subject within two weeks of patient identification.

Just-In-Time methodology to jump-start study enrollment

Pre-study	Just-in-time	10-14 days	
Community of sites with pre-negotiated contracts/terms	Immediate engagement by sites to search for patients	Patients identified and site activated	Patients enrolled within two weeks of identification

Benefits



Diversity

Just-in-time sites are concentrated in ethnically diverse areas



Performance

Opportunity to accelerate overall study performance



Patient-centric

Exposing more trial options to patients while allowing sites to focus on studies for which they have patients



Risk Management

Mitigate risk from non-enrolling sites; risk mitigation strategy is available from day one



Efficiency

Improved efficiencies/volume through protocol stacking

The PPD clinical research business of Thermo Fisher Scientific is a proven and experienced global leader in oncology clinical research- providing industry leading oncology solutions for more than 20 years.



**Scan
to learn
more**

References

1. Kasner M, Fritsche AH, Leong MC, et al. North American Cancer Center Clinical Research Capacity and Benchmarking in the Postpandemic Era. JCO Oncology Practice. 2024;20(12):1612-1619. doi:10.1200/OP.24.00164.
2. Ratnayake I, Do A-T, Gajewski D, et al. Evaluating the impact of delayed study startup on accrual in cancer studies. Contemporary Clinical Trials Communications. 2025;48:101562. doi:10.1016/j.conctc.2025.101562.

Learn more at ppd.com/therapeutic-expertise

ppd